OHC is the first, most experienced, and only certified independent adult cancer practice in the region to offer the revolutionary immunotherapy treatments, CAR-T and NK cell therapy, for adults, ushering in a new frontier in the fight against cancer.

OHC’s clinical research program is one of a select group in the nation chosen to participate in revolutionary bi-specific T-cell therapy (BiTE) Phase 1 clinical trials.

OHC is certified by the American Society of Clinical Oncology (ASCO) in the Quality Oncology Practice Initiative Certification Program (QOPI) for achieving rigorous standards for high quality cancer care.

OHC doctors serve as Medical Director of the nationally-recognized, FACT-accredited Blood and Marrow Transplant Program at The Jewish Hospital – Mercy Health. The hospital’s program has earned The Joint Commission’s prestigious Gold Seal of Approval.

OHC is accredited in radiation oncology by the American College of Radiology. This accreditation represents the highest level of quality and patient safety.

OHC offers clinical trials through the Sarah Cannon Research Institute (SCRI), one of the world’s leading cancer research organizations conducting community-based clinical trials, whose work has led to the majority of new cancer therapies approved by the FDA today. The collaboration includes OHC in a network of globally recognized cancer experts enrolling patients in phase 1-4 clinical trials at more than 250 locations across 24 U.S. states.

OHC is an American Society of Clinical Oncology Clinical Trial Award Winner for its dedication to conquering cancer worldwide by funding breakthrough cancer research and sharing cutting-edge knowledge.

OHC is one of only six community oncology practices in the country that has been recognized by the Conquer Cancer Foundation of the American Society of Clinical Oncology for its commitment to high-quality clinical trial programs.

The OHC Specialty Retail Pharmacy is accredited by the Accreditation Commission for Health Care (ACHC). By achieving this distinction, the OHC Pharmacy is able to demonstrate its commitment to providing the highest-quality service through compliance with national regulations and industry best practices.

OHC is an accredited Oncology Medical Home, which focuses on delivering, ensuring, and measuring quality cancer care and relies on a doctor-led, team-based healthcare model that provides comprehensive and continuous care to cancer patients with a goal of obtaining maximized health outcomes.

OHC is the only practice, and one of six recipients, of the 2023 Innovation Award from the Association of Community Cancer Centers (ACCC) for its groundbreaking quality improvement project focusing on comprehensive biomarker testing in patients with metastatic non-small cell lung cancer. This project is being implemented by other cancer practices across the nation.